ガロイ化リポソームは,タンパク質のコロナシールドを克服することによって,標的の薬物投与を可能にします
Jinbo Li1, Jiang Yu1, Jia Song1
1Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.
Nature communications
|August 25, 2025
まとめ
研究者らは,標的型薬物投与のためのガロイ化リポソーム (GA-リポ) を開発した. この新しいナノ医学のアプローチは タンパク質コロナの課題と 製造の複雑さを克服し 薬の蓄積と腫瘍抑制を 改善します
科学分野:
- ナノ医療
- 薬物投与システム
- バイオテクノロジー
背景:
- リンガンドを標的としたナノ医薬品は 精密な薬剤投与が可能ですが タンパク質コロナ形成や複雑な製造などの課題に直面しています
- タンパク質コロナは,標的となるリガンドを覆い,ナノ医療の有効性を低下させ,臨床翻訳を妨げます.
研究 の 目的:
- 安定した機能的なリガンド結合のための新しいナノ医療プラットフォーム,ガロイ化リポソーム (GA-リポ) を開発する.
- タンパク質のコロナ干渉を克服し,標的型医薬品の製造を簡素化する.
主な方法:
- GA-リポを生成するために,ガリック酸で改変された脂質をリポソームに組み込む.
- ターゲティングリガンド (トラストズマブ) の安定した非共性吸収がGA-リポに発生する.
- リポソームに薬物 (DXdd) をリモートロードし,その後にリガンド機能化を行う.
主要な成果:
- GA- lipoは安定したリガンド吸収を可能にし,タンパク質コロナでもリガンドの方向性と機能性を保持した.
- 100 nmのリポソームでDXddの95%の封じ込め効率を達成した.
- トラストズマブで機能化された免疫リポソームは,SKOV3腫瘍モデルで増強された腫瘍阻害を示した.
結論:
- GA-lipoは,標的型ナノ医薬品配送システムを構築するためのシンプルでスケーラブルで効果的なプラットフォームを提供します.
- このアプローチは,ナノ医療開発における重要な課題に対応し,広範な臨床適用性を示しています.
- 開発された免疫リポソームは腫瘍抑制を大幅に改善し,GA-リポ技術の可能性を強調しています.
関連する概念動画
Lipids as Anchors
In the plasma membrane, the lipids forming the bilayer can also act as an anchor to tether proteins to the membrane. The three main types of lipid anchors found in eukaryotes are – prenyl groups, fatty acyl groups, and glycosylphosphatidylinositol or GPI groups. Prenyl and fatty acyl groups act as anchors on the cytosolic surface of the membrane, whereas GPI anchors proteins on the extracellular side.
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains the...
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains the...
Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


